{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T12:04:10Z","timestamp":1765713850657,"version":"build-2065373602"},"reference-count":47,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.urolonc.2011.06.004","type":"journal-article","created":{"date-parts":[[2011,7,25]],"date-time":"2011-07-25T11:36:10Z","timestamp":1311593770000},"page":"849-856","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy?"],"prefix":"10.1016","volume":"31","author":[{"given":"Jinsung","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheryn","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eunah","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun Hyuk","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Choung-Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanjong","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2011.06.004_bib1","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1016\/j.juro.2007.09.003","article-title":"Guideline for the management of non-muscle-invasive bladder cancer (stages Ta, T1, and Tis): 2007 update","volume":"178","author":"Hall","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2011.06.004_bib2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000019664","article-title":"Low-dose BCG instillations in the treatment of stage T1 grade 3 bladder tumours: Recurrence, progression and success","volume":"34","author":"Lebret","year":"1998","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2011.06.004_bib3","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ucl.2005.02.002","article-title":"Optimal management of the T1G3 bladder cancer","volume":"32","author":"Manoharan","year":"2005","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.urolonc.2011.06.004_bib4","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0090-4295(98)00369-0","article-title":"Intravesical bacillus Calmette-Guerin treatment for Stage T1 grade 3 transitional cell carcinoma of the bladder","volume":"52","author":"Baniel","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2011.06.004_bib5","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1046\/j.1464-410X.1997.00431.x","article-title":"Tumour progression and survival in patients with T1G3 bladder tumours: 15-Year outcome","volume":"80","author":"Herr","year":"1997","journal-title":"Br J Urol"},{"key":"10.1016\/j.urolonc.2011.06.004_bib6","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0022-5347(01)66043-9","article-title":"Reassessment of conservative management for stage T1N0M0 transitional cell carcinoma of the bladder","volume":"155","author":"Zhang","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2011.06.004_bib7","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0302-2838(02)00173-2","article-title":"Intravesical bacillus Calmette-Guerin treatment improves patient survival in T1G3 bladder tumours","volume":"41","author":"Patard","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2011.06.004_bib8","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.eururo.2007.06.030","article-title":"Early vs. deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: Do risk factors define feasibility of bladder-sparing approach?","volume":"53","author":"Denzinger","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2011.06.004_bib9","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0022-5347(05)65756-4","article-title":"Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?","volume":"166","author":"Herr","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2011.06.004_bib10","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2011.06.004_bib11","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0090-4295(99)00116-8","article-title":"Intravesical bacillus Calmette-Guerin in Stage T1 grade 3 bladder cancer therapy: A 7-year follow-up","volume":"54","author":"Hurle","year":"1999","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2011.06.004_bib12","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00345-008-0350-4","article-title":"Prognostic significance of non-papillary tumor morphology as a predictor of cancer progression and survival in patients with primary T1G3 bladder cancer","volume":"27","author":"Park","year":"2009","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2011.06.004_bib13","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0022-5347(05)67281-3","article-title":"The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer","volume":"164","author":"Solsona","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2011.06.004_bib14","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0090-4295(01)01603-X","article-title":"Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacillus Calmette-Guerin: 18-Year experience","volume":"59","author":"Pansadoro","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2011.06.004_bib15","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/nm0798-844","article-title":"Tissue microarrays for high-throughput molecular profiling of tumor specimens","volume":"4","author":"Kononen","year":"1998","journal-title":"Nat Med"},{"key":"10.1016\/j.urolonc.2011.06.004_bib16","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1200\/JCO.2004.03.118","article-title":"p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer","volume":"22","author":"Shariat","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2011.06.004_bib17","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.juro.2006.09.038","article-title":"Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma","volume":"177","author":"Shariat","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2011.06.004_bib18","first-page":"1090","article-title":"Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53","volume":"58","author":"Cote","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2011.06.004_bib19","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S0022-5347(05)67798-1","article-title":"The role of bcl-2, p53, and ki-67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma","volume":"163","author":"Wu","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2011.06.004_bib20","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S0022-5347(01)61770-1","article-title":"Correlation and prognostic significance of p53, p21WAF1\/CIP1, and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy","volume":"161","author":"Zlotta","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2011.06.004_bib21","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/ijc.11049","article-title":"Ki-67 index enhances the prognostic accuracy of the urothelial superficial bladder carcinoma risk group classification","volume":"105","author":"Santos","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.urolonc.2011.06.004_bib22","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000049768","article-title":"Prospective evaluation of Ki-67 labeling in predicting the recurrence and progression of superficial bladder transitional cell carcinoma","volume":"40","author":"Blanchet","year":"2001","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2011.06.004_bib23","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ejso.2005.11.018","article-title":"FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer","volume":"32","author":"Mhawech-Fauceglia","year":"2006","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.urolonc.2011.06.004_bib24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.urolonc.2006.08.021","article-title":"Tissue microarray based analysis of prognostic markers in invasive bladder cancer: Much effort to no avail?","volume":"26","author":"Liedberg","year":"2008","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2011.06.004_bib25","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/1097-0215(20001115)88:4<620::AID-IJC16>3.0.CO;2-Z","article-title":"Molecular analysis of PTEN and MXI1 in primary bladder carcinoma","volume":"88","author":"Wang","year":"2000","journal-title":"Int J Cancer"},{"key":"10.1016\/j.urolonc.2011.06.004_bib26","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/sj.gt.3302056","article-title":"In vivo gene therapy of human bladder cancer with PTEN suppresses tumor growth, down-regulates phosphorylated Akt, and increases sensitivity to doxorubicin","volume":"10","author":"Tanaka","year":"2003","journal-title":"Gene Ther"},{"key":"10.1016\/j.urolonc.2011.06.004_bib27","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1002\/cncr.11698","article-title":"Motility-related protein 1 (MRP-1\/CD9) expression in urothelial bladder carcinoma and its relation to tumor recurrence and progression","volume":"98","author":"Mhawech","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2011.06.004_bib28","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1159\/000127338","article-title":"Clinical value of PTEN in patients with superficial bladder cancer","volume":"80","author":"Han","year":"2008","journal-title":"Urol Int"},{"key":"10.1016\/j.urolonc.2011.06.004_bib29","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0022-5347(01)64825-0","article-title":"Long-term efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ: Relationship of progression to histological response and p53 nuclear accumulation","volume":"157","author":"Ovesen","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2011.06.004_bib30","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0090-4295(01)01551-5","article-title":"Prognostic value of p53 overexpression in T1G3 bladder tumors treated with bacillus Calmette-Guerin therapy","volume":"59","author":"Peyromaure","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2011.06.004_bib31","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.eururo.2003.11.011","article-title":"Prognostic factors in stage T1 grade 3 bladder cancer survival: The role of G1-S modulators (p53, p21Waf1, p27kip1, cyclin D1, and cyclin D3) and proliferation index (ki67-MIB1)","volume":"45","author":"Lopez-Beltran","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2011.06.004_bib32","first-page":"829","article-title":"p53 and RB expression predict progression in T1 bladder cancer","volume":"4","author":"Grossman","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2011.06.004_bib33","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1200\/JCO.2004.05.174","article-title":"Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma","volume":"22","author":"Chatterjee","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2011.06.004_bib34","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1046\/j.1464-410X.1997.06911.x","article-title":"Nuclear accumulation of mutant p53 protein: A possible predictor of failure of intravesical therapy in bladder cancer","volume":"79","author":"Caliskan","year":"1997","journal-title":"Br J Urol"},{"key":"10.1016\/j.urolonc.2011.06.004_bib35","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/S0022-5347(01)63731-5","article-title":"Correlation between p53 over expression and response to bacillus Calmette-Guerin therapy in a high risk select population of patients with T1G3 bladder cancer","volume":"159","author":"Lebret","year":"1998","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2011.06.004_bib36","first-page":"81","article-title":"p53 and human cancer: The first ten thousand mutations","volume":"77","author":"Hainaut","year":"2000","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.urolonc.2011.06.004_bib37","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1038\/bjc.1998.371","article-title":"Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: High frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis","volume":"77","author":"Abdel-Fattah","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2011.06.004_bib38","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/jnci\/84.16.1251","article-title":"Altered expression of the retinoblastoma gene product: Prognostic indicator in bladder cancer","volume":"84","author":"Cordon-Cardo","year":"1992","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2011.06.004_bib39","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.urolonc.2008.08.003","article-title":"Retinoblastoma protein expression predicts response to bacillus Calmette-Guerin immunotherapy in patients with T1G3 bladder cancer","volume":"28","author":"Cormio","year":"2010","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2011.06.004_bib40","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1159\/000050635","article-title":"Prognostic value of p53, p21\/WAF1, Bcl-2, Bax, Bak, and Ki-67 immunoreactivity in pT1 G3 urothelial bladder carcinomas","volume":"22","author":"Wolf","year":"2001","journal-title":"Tumor Biol"},{"key":"10.1016\/j.urolonc.2011.06.004_bib41","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1159\/000020233","article-title":"Prognostic value of MIB-1 antibody labeling index to predict response to bacillus Calmette-Guerin therapy in a high-risk selected population of patients with stage T1 grade G3 bladder cancer","volume":"37","author":"Lebret","year":"2000","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2011.06.004_bib42","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1158\/0008-5472.CAN-03-2421","article-title":"FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma","volume":"64","author":"van Rhijn","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2011.06.004_bib43","first-page":"8108","article-title":"FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder","volume":"63","author":"Bakkar","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2011.06.004_bib44","doi-asserted-by":"crossref","first-page":"5444","DOI":"10.1158\/1078-0432.CCR-05-0122","article-title":"FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: Independent distribution and lack of association with prognosis","volume":"11","author":"Hernandez","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2011.06.004_bib45","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1016\/j.juro.2006.07.132","article-title":"Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations","volume":"176","author":"Lamy","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2011.06.004_bib46","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/1096-9896(200107)194:3<349::AID-PATH887>3.0.CO;2-D","article-title":"Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade","volume":"194","author":"Nocito","year":"2001","journal-title":"J Pathol"},{"key":"10.1016\/j.urolonc.2011.06.004_bib47","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1097\/01.ju.0000073852.24341.4a","article-title":"Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer","volume":"170","author":"Bohle","year":"2003","journal-title":"J Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143911001918?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143911001918?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:00:04Z","timestamp":1761040804000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143911001918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S1078143911001918"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2011.06.004","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy?","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2011.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}